Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis

Table 3 Subgroup analysis of association between BPs and BMD for each variable

Variable	No. of trials	No. of participants		MD	95% CI	p value
Variable	No. of trials	BPs	Control	MD	95% CI	p value
1 year after THA
Type of THA
Cemented	2	38	31	0.06	0.00–0.13	0.76
Uncemented	9	202	194	0.05	0.02–0.09	0.76
Treatment duration of BPs
≤ 6 months	5	96	88	0.04	− 0.01–0.10	0.32
> 6 months	6	124	122	0.07	0.04–0.09	0.32
2–4 year after THA
Type of THA
Cemented	1	20	18	0.05	0.02–0.09	0.46
Uncemented	4	80	88	0.07	0.03–0.11	0.46
Treatment duration of BPs
≤ 6 months	4	86	86	0.03	− 0.03–0.09	0.32
> 6 months	2	36	42	0.06	0.03–0.10	0.32
≥ 5 year after THA
Type of THA
Cemented	0	0	0	Not estimable	Not estimable	NA
Uncemented	3	54	45	0.09	0.07–0.11	NA
Treatment duration of BPs
≤ 6 months	3	54	48	0.03	− 0.03–0.10	0.12
> 6 months	1	18	16	0.09	0.07–0.11	0.12

THA total hip arthroplasty, BPs bisphosphonates, MD mean differences, CI confidence interval, NA not applicable

ISSN: 1749-799X